
Keywords: nontuberculous mycobacteria; pulmonary disease; treatment outcome; AMX; amikacin; ATS; American Thoracic Society; AZT; azithromycin; CFZ; clofazimine; Clari; clarithromycin; LAI; liposomal AMX for inhalation; MAC; Mycobacterium avium complex; MAC-PD; MAC